CA 02351315 2001-05-17
HUMANIZED ANTIBODY SPECIFIC FOR SURFACE ANTIGEN PRE-S1
OF HBV AND PREPARATION METHOD THEREOF
FIELD OF THE INVENTION
The present invention relates to humanized
antibodies specific for HBV surface antigen pre-S1.
Particularly, this invention relates to humanized
antibodies specific for HBV surface antigen pre-S1, the
antibody comprising humanized heavy and light chain; to
genes encoding the humanized heavy or light chain; to
expression vectors containing said genes and E. coli
transformants containing said expression vector; and to
pharmaceutical composition comprising said humanized
antibody, which may be administered in order to prevent
HBV infection or to treat chronic hepatitis B.
BACKGROUND
HBV (Hepatitis B Virus) is responsible for chronic
or acute human hepatitis that may get worse to liver
cirrhosis or cancer. It is estimated that about three
hundred million people are suffering from hepatitis in
the world (Tiollais and Buendia, Sci. Am. 264:48, 1991).
There are three kinds of HBV surface proteins
containing different sets of surface antigens.
Particularly, these surface antigen proteins includes
the Major Protein containing S antigen, the Middle
1
CA 02351315 2001-05-17
Protein containing S and pre-S2 antigens, and the Large
Protein containing S, pre-S2 and pre-S1 antigens
(Neurath and Kent, Adv. Virus Res., 34:65-142, 1988).
All the surface antigen proteins can induce antibodies
that neutralize HBV, and especially, antibodies against
HBV pre-S antigen are associated with the elimination
of the virus and the recovery from HBV infection,
overcoming non-responsiveness to the S antigen (Iwarson
et al., J. Med. Virol., 16:89-96, 1985; Itoh et al.,
Proc. Natl. Acad. Sci. USA, 85:9174-9178, 1986;
Budkowska et al., J. Med. Virol., 20:111-125, 1986;
Milich et al., Proc. Natl. Acad. Sci. USA, 82:8168-8172,
1985; Milich et al., J. Immunol., 137:315-322, 1986).
Unlike pre-S2 or S antigen, pre-Sl antigen is
exclusively present in infectious virus particles
(Heerman et al., J. Virol., 52:396-402, 1984) and
involved in the infection into human liver cells. Thus,
it has been reported that monoclonal antibody specific
for pre-Sl antigen may efficiently neutralize HBV
(Neurath et al., Cell, 46:429, 1986; Pontisso et al.,
Virology, 173:533, 1989; Neurath et al., Vaccine, 7:234,
1989), and the monoclonal antibody is considered to be
useful in the prevention of HBV infection and the
treatment of chronic hepatitis B.
So far hepatitis B immunoglobulin has been
employed as a preventive for HBV infection, which may
2
CA 02351315 2001-05-17
protect, for example, a newborn baby from a HBV-
positive mother, medical personnel exposed to HBV, and
liver transplant patient with chronic HBV-related liver
disease (Beasley et al., Lancet, 2:1099, 1983; Todo et
al., Hepatology, 13:619, 1991). However, hepatitis B
immunoglobulin has some shortcomings such as its
limited availability, low specific activity and its
possible contamination with infectious agents.
Furthermore, it is another disadvantage of hepatitis B
immunoglobulin that blood plasma should be continuously
supplied.
As an alternative for the hepatitis B
immunoglobulin, mouse monoclonal antibodies against HBV
surface antigens have been developed. Although the
mouse monoclonal antibodies show high affinity for the
antigen and can be prepared on a large scale, they
induce human anti-mouse antibody response in patients
(Shawler et al., J. Immunol., 135:1530, 1985). There
were attempts to prepare human monoclonal antibodies,
but few of these antibodies showed a high level of
affinity.
Instead, humanized antibodies have been developed.
Humanized antibody has a high level of affinity and
specificity similar to mouse antibodies, whereas its
immunogenicity is minimized. Humanized antibody is a
hybrid antibody in which CDRs (Complementarity
Determining Regions) of a mouse antibody is grafted to
3
CA 02351315 2001-05-17
a human antibody by genetic engineering technique. It
can be easily prepared on a large scale, and hardly
elicits immune responses in humans since most of the
DNA sequences encoding the humanized antibodies are
derived from a human DNA sequence (Riechman et al.,
Nature, 332:323, 1988; Nakatani et al., Protein
Engineering, 7:435, 1994).
To overcome the aforementioned and other
disadvantages of mouse or human HBV immunoglobulin, we,
the inventors of the present invention, have attempted
to prepare humanized antibodies which can be used to
prevent HBV infection and to treat chronic hepatitis B.
Prior to this invention, we prepared a mouse monoclonal
antibody KR127 against HBV surface antigen pre-Sl.
Additionally, we isolated the genes encoding the heavy
and light chain variable regions of KR127 antibody and
determined the sequences of the genes (Korea Patent
Application No. 1997-30696). The present invention is
performed by selecting human immunoglobulin genes
homologous to the sequences of KR127 antibody light
chain and heavy chain variable regions; constructing
the humanized antibody genes; inserting the genes into
expression vectors; introducing the vectors into host
cells; obtaining humanized antibodies from the culture
of the transformed cells; and confirming that the
humanized antibodies have high affinity to HBV pre-S1
4
CA 02351315 2004-07-20
antigen, similar to the mouse monoclonal antibody KR127.
SUMMARY OF THE INVENTION
It is an object of an aspect of this invention to
provide humanized antibodies specific for CDRs of mouse
HBV surface antigen pre-S1, having high affinity to the
antigen and reduced immunogenicity in human.
In accordance with the present invention, the
foregoing objects of aspects of the invention and
advantages are readily obtained.
The present invention provides humanized antibodies
specific for HBV surface antigen pre-S1, comprising
humanized heavy and light chains.
This invention also provides genes encoding the
variable regions of said humanized heavy or light chain.
In addition, this invention provides expression
vectors containing said genes and E. coli transformants
containing said expression vectors.
This invention further provides pharmaceutical
compositions comprising said humanized antibody, which
may be administered in order to prevent HBV infection or
to treat chronic hepatitis B.
In accordance with one embodiment of the present
invention, there is provided a humanized antibody
specific for Hepatitis B virus (HBV) surface antigen pre-
Sl, comprising a humanized heavy chain variable region
which comprises the amino acid sequence described by SEQ
ID NO: 20.
In accordance with another embodiment of the present
invention, there is provided a humanized antibody
specific for HBV surface antigen pre-S1, comprising a
humanized heavy chain variable region which comprises the
amino acid sequence described by SEQ ID NO: 21.
5
CA 02351315 2004-07-20
In accordance with another embodiment of the present
invention, there is provided a humanized antibody
specific for HBV surface antigen pre-S1, comprising a
humanized light chain variable region which comprises the
amino acid sequence described by SEQ ID NO: 23.
In accordance with a further embodiment of the
present invention, there is provided a gene encoding a
humanized heavy chain which comprises a humanized heavy
chain variable region as described in any of the three
preceding paragraphs..
In accordance with a further embodiment, an
expression vector comprises a gene as described above.
A further embodiment is the expression vector
deposited under Accession Number KCTC 0531BP.
A further embodiment is the expression vector
deposited under Accession Number KCTC 0691BP.
A further embodiment is the expression vector
deposited under Accession Number KCTC 0529BP.
A further embodiment is a pharmaceutical composition
comprising a humanised antibody as described above.
A further embodiment is use of the humanized
antibody described above to prevent HBV infection or to
treat chronic hepatitis B.
Further features of the present invention will
appear hereinafter.
5a
CA 02351315 2001-05-17
BRIEF DESCRIPTION OF THE DRAWINGS
FIG la and FIG lb comparatively depict the amino
acid and nucleotide sequences of VH regions (for
Variable regions of Heavy chains) in a mouse monoclonal
antibody KR127 and in two humanized antibodies of this
invention,
FIG 2a schematically depicts a process for
preparing HKR127HC(I) gene encoding the heavy chain of
a humanized antibody of this invention,
FIG 2b schematically depicts a process for
preparing HKR127HC(III) gene encoding the heavy chain
of a humanized antibody of this invention,
FIG 3a and FIG 3b comparatively depict the amino
acid and nucleotide sequences of VL regions (for
Variable regions in Light chain) in a mouse monoclonal
antibody KR127 and in a humanized antibody of this
invention.
FIG 4 schematically depicts a process for
preparing HKR127KC(I) gene encoding a humanized
antibody of this invention,
FIG 5a depicts an expression vector pCMV-HKR127HC
containing a gene for heavy chain of the humanized
antibody,
FIG 5b depicts an expression vector pKC-dhfr-
HKR127 containing a gene for light chain of the
humanized antibody,
6
CA 02351315 2001-05-17
FIG 5c depicts an expression vector pCMV-
HKR127HC(III) containing a gene for heavy chain of the
humanized antibody,
FIG 6a comparatively shows the binding affinities
of a humanized antibody (HZKR127I) and a mouse
monoclonal antibody (KR127), and
FIG 6b comparatively shows the binding affinities
of a humanized antibody (HZKR127III) and a humanized
antibody (HZKR127I).
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
Hereinafter, the present invention is described in
detail.
This invention provides humanized antibodies
specific for HBV surface antigen pre-Sl, comprising
humanized heavy and humanized light chains.
This invention also provides genes encoding the
variable regions of said humanized heavy or light chain.
Said humanized heavy chain contains variable
region which is derived from the VH region of mouse
KR127 antibody. The VH region of mouse KR127 antibody
is described by SEQ ID N0: 19, and the VH region of the
humanized antibody of this invention can be prepared by
grafting the CDRs of mouse KR127 VH region to
homologous human immunoglobulin VH region.
And said humanized light chain contains variable
7
CA 02351315 2001-05-17
region which is derived from the VL region of mouse
KR127 antibody. The VL region of mouse KR127 antibody
is described by SEQ ID N0: 22, and the VL region of the
humanized antibody of this invention can be prepared by
grafting the CDRs of mouse KR127 VL region to
homologous human immunoglobulin VL region.
In preferred embodiments, we screened human
immunoglobulin that show the highest similarities of
amino acid sequence to the heavy or light chain of the
mouse monoclonal antibody KR127. In result, human
immunoglobulin germ line genes DP7 and DPK12 were
screened from GenBank database. DP7 shows the highest
homology to the VH region of mouse antibody KR127,
while DPK12 is most similar to the VL region of KR127.
The humanized antibodies of this invention can be
produced from recombinant genes encoding humanized VH
region or VL region. These genes are constructed by
substituting CDRs of mouse KR127 for those of the human
DP7 or DPK12 antibody. In constructing these genes,
most of the amino acid residues corresponding to the
humanized CDRs are derived from the CDRs of mouse
antibody KR127. However, some mouse-derived CDRs
residues are replaced by human counterparts, since
their corresponding amino acid residues are expected
not to be involved in the antigen binding (see FIG 1).
In the same way, some human-derived amino acid residues
for the non-CDR framework regions (FR) of variable
8
CA 02351315 2001-05-17
region are replaced with mouse counterparts, since it
is expected that these FR residues may affect the
conformation of CDRs.
Particularly, HKR127HCv(HZII) gene encoding a
humanized VH region was prepared by grafting the
partial CDRl, 2, 3 and a FR residue (at position 72) of
mouse KR127 heavy chain to the human DP7 gene (see FIG
1) .
However, antibody expressed from HKR127HCv(HZII)
gene did not show any significant level of binding
capacity to corresponding antigen. To improve the
HKR127HCv(HZII) gene, we also prepared HKR127HCv(HZI)
gene and HKR127HCv(HZIII) gene which contain more
mouse-derived codons than HKR127HCv(HZII) gene (see FIG
1) .
HKR127HCv(HZI) contains CDRl, partial CDR2, and
CDR3, and 11 FR residues of mouse KR127 VH, while
HKR127HCv(HzIII) contains the same mouse CDR codons and
2 mouse FR residues (see FIG 1).
To construct HKR127HC(I) gene encoding a full-
length heavy chain of the humanized antibody of this
invention, PCRs were conducted, in which template for
amplification is either the HKR127HCv(HZII) gene or
pRC/CMV-HC-HuS (KCTC 0229BP) containing the heavy chain
leader sequence and the constant region sequence of
human immunoglobulin heavy chain yl.
Six pairs of oligonucleotides (SEQ ID N0: 1 and 2;
9
CA 02351315 2004-07-20
3 and 4; 5 and 6; 7 and 8; 9 and 10; and 11 and 12)
were used as PCR primers (see FIG 2a).
The first five PCR products were brought to
annealing reaction. Then, the DNA fragment containing
the five PCR products was employed as a template of
recombinant PCR wherein two primers described by SEQ ID
N0: 1 and 10 were used. Another recombinant PCR was
conducted to link the amplified 431-by DNA fragment to
DNA fragment which was obtained by PCR using two
primers (described by SEQ ID NO: 11 and 12). The
recombinant PCR employed two primers described by SEQ
ID NO: 1 and 12. The final 1431-by PCR product,
HKR127HC(I), encoding the heavy chain of a humanized
antibody (HZKR127I) was introduced into pBluescript~
SK(+) vector (Clontech), and the resulting vector was
designated pHKR127HC(I).
The primers are described in SEQ ID NO: 1 to 12 in
SEQUENCE LISTING, and particularly, primer described by
SEQ ID NO: 1 contains EcoRI sequence at the 5' end,
while primer described by SEQ ID NO: 12 does SalI
sequence at the 3' end.
The variable region in the HKR127HC(I) gene
contains 11 mouse-derived FR residues at positions 12,
28, 30, 48, 67, 68, 70, 72, 74, 79 and 95 (see FIG 1) .
The heavy chain variable region has 87 FR residues, and
the unmodified FR residues is 76. Thus, the amino acid
sequence of the heavy chain variable FR of the
Trade-mark 10
CA 02351315 2001-05-17
HKR127HC(I) gene is 87o homologous to that of human DP7
gene.
To more humanize the HZKR127(I), HZKR127(III) gene
was constructed, which contains HKR127HCv(HZIII) gene
with 2 mouse-derived FR residues at position 72 and 74
( see FIG 1 ) .
To construct HKR127HC(III) gene encoding a full-
length heavy chain of the humanized antibody of this
invention, PCRs were conducted, in which template for
amplification is either the HKR127HCv(HZII) gene or
pRC/CMV-HC-HuS (KCTC 0229BP) containing the heavy chain
leader sequence and the constant region sequence of
human immunoglobulin heavy chain y1 (see FIG 2b).
Four pairs of oligonucleotides (SEQ ID NO: 1 and
24; 25 and 26; 27 and 28; and 11 and 12) were used as
PCR primers (see FIG 2b). The first three PCR products
were brought to annealing reaction. Then, the DNA
fragment containing the three PCR products was employed
as a template of recombinant PCR wherein two primers
described by SEQ ID N0: 1 and 28 were used. Another
recombinant PCR was conducted to link the amplified
431-by DNA fragment to DNA fragment which was obtained
by PCR using two primers (described by SEQ ID N0: 11
and 12). The recombinant PCR employed two primers
described by SEQ ID N0: 1 and 12.
The final 1431-by PCR product, HKR127HC(III),
encoding the heavy chain of a humanized antibody
11
CA 02351315 2001-05-17
(HZKR127III) was introduced into pBluescript SK(+)
vector (Clontech), and the resulting vector was
designated pHKR127HC(III).
In a further embodiment, HKR127KCv(HZII) gene
encoding a humanized VL region was prepared by grafting
the CDR1, CDR3 and partial CDR2 of mouse KR127 light
chain to the human DPK12 gene (see FIG 3).
However, antibody expressed by using the
HKR127KCv(HZII) gene did not show any significant level
of binding capacity to corresponding antigen. To
improve the binding capacity of HKR127KCv(HZII), we
also prepared HKR127KCv(HZI) gene which contains more
mouse-derived amino acid residues (see FIG 3) than
HKR127HKCv(HZII) (see FIG 3).
To construct HKR127KC(I) gene encoding a full-
length light chain of the humanized antibody of this
invention, PCRs were conducted, in which template for
amplification is either the HKR127KCv(HZII) gene or
pKC-dfhr-HuS (KCTC 0230BP) containing the light chain
leader sequence and the constant region sequence of
human immunoglobulin light chain K.
Three pairs of oligonucleotides (SEQ ID N0: 13 and
14; 15 and 16; and 17 and 18) were used as PCR primers
(see FIG 4).
The first two PCR products were brought to
annealing reaction. Then, the DNA fragment containing
12
CA 02351315 2001-05-17
the two PCR products was employed as a template of
recombinant PCR wherein two primers described by SEQ ID
NO: 13 and 16 were used. Another recombinant PCR was
conducted to link the amplified 360-by DNA fragment to
DNA fragment which was obtained by PCR using two
primers (described by SEQ ID N0: 17 and 18). The
recombinant PCR employed two primers which are
described by SEQ ID N0: 13 and 18. The final 739-by
PCR product, HKR127KC(I), encoding the light chain of a
humanized antibody (HZKR127I) was introduced into
pBluescript SK(+) vector (Clontech), and the resulting
vector was designated pHKR127KC(I).
The primers are described in SEQ ID N0: 13 to 18
in SEQUENCE LISTING, and particularly, primer described
by SEQ ID NO: 13 contains HindIII sequence at the 5'
end, while primer described by SEQ ID NO: 18 does SalI
sequence at the 3' end.
The variable region FR of the HKR127KC gene
contains 5 mouse KR127-derived codons (see FIG 3). The
light chain has 83 FR residues, and the unmodified FR
residues is 78. Thus, the amino acid sequence of the
light chain variable FR of the HKR127KC gene is 940
identical to that of human DP7 gene.
In addition, this invention provides expression
vectors containing genes encoding the humanized VH or
VL region and provides E. coli transformants containing
13
CA 02351315 2001-05-17
said expression vector.
In other preferred embodiments, expression vectors
are prepared, which contain the gene encoding the heavy
or light chain of humanized antibody (see FIG 5a, 5b or
5c ) .
Particularly, two kinds of DNA fragment
corresponding to humanized heavy chain was respectively
obtained from the plasmids pHKR127HC(I) and
pHKR127HC(III) by treatment of restriction enzymes, and
then inserted into pRc/CMV (Invitrogen) to give
expression vector pCMV-HKR127HC (see FIGSa) and pCMV-
HKR127(III)HC (see FIG 5c), respectively.
In addition, DNA fragment encoding the humanized
light chain was isolated from the pHKR127KC vector, and
then introduced into pCMV-dfhr (KCTC 8671P) to
construct expression vector pKC-dhfr-HKR127 (see FIG
5b ) .
E. coli strain DHSa was transformed with the
expression vector pCMV-HKR127HC, pCMV-HKR127(III)HC or
pKC-dhfr-HKR127. The resulting E. coli transformants
containing pCMV-HKR127HC or pKC-dhfr-HKR127 were
deposited in KCTC (Korean Collection for Type Culture)
(Accession Number: KCTC 0531BP and KCTC 0529BP,
respectively) on October 12, 1998. The E, coli
transformant containing pCMV-HKR127(III)HC was
deposited in KCTC (Accession Number: KCTC 0691BP,
respectively) on November 15, 1999.
14
CA 02351315 2001-05-17
In another preferred embodiment, humanized
antibodies specific for HBV surface antigen pre-S1 were
expressed in animal cells and obtained from culture
media of the cells. COS7 cells were transiently
cotransfected with the expression vectors pCMV-HKR127HC
and pKC-dhfr-HKR127, and the resulting transfected
cells was cultured and the culture supernatant was used
to characterize a humanized antibody HZKR127I of the
present invention. COS7 cells were also cotransfected
with the expression vectors pCMV-HKR127(III)HC and pKC-
dhfr-HKR127, and the culture supernatant of transfected
cells was used to characterize a humanized antibody
HZKR127III.
This invention further provides pharmaceutical
compositions containing said humanized antibody.
According to still other preferred embodiments, it
was verified that HZKR127I and HZKR127III humanized
antibodies of the present invention, showed almost same
antigen-binding affinity when compared with mouse
monoclonal antibody KR127 (see Table l, 2 and FIG 6a,
6b ) .
The composition includes a therapeutically
effective amounts of the humanized antibody against HBV
antigen pre-Sl, with/without a pharmaceutically
acceptable delivery vehicle. Moreover, the
CA 02351315 2001-05-17
compositions may include other anti-hepatitis drug(s),
such as anti-S monoclonal antibody or lamivudin.
The humanized antibody against HBV antigen pre-Sl
may be formulated with a pharmaceutical vehicle or
diluent for intravenous, subcutaneous, intramuscular
administration. The pharmaceutical composition can be
formulated in a classical manner using solid or liquid
vehicles, diluents and additives appropriate to the
desired mode of administration.
The humanized antibody of this invention may be
administered in a dosage range of about 1 ~ 10 mg/kg,
preferably 3 ~ 5 mg/kg, and may be administered once a
week.
EXAMPT,F S
Practical and presently preferred embodiments of
the present invention are illustrative as shown in the
following Examples.
However, it will be appreciated that those skilled
in the art, on consideration of this disclosure, may
make modifications and improvements within the spirit
and scope of the present invention.
16
CA 02351315 2001-05-17
Example l: Preparation of gene encoding humanized heavy
_,~___
In order to construct the humanized heavy chain
variable region gene, first, we selected a human
immunoglobulin heavy chain gene that shows the highest
homology of amino acid sequence to the heavy chain
variable region of the mouse monoclonal antibody KR127.
As the result, a human immunoglobulin germ line gene
DP7 was selected from GenBank database. Then, we
constructed a humanized VH region gene HKR127HCv(HZII)
by DNA recombination techniques, which was based upon
the comparison of the mouse KR127 VH region with the
human DP7 VH region. Since the humanized heavy chain
did not show significant antigen binding activity, we
prepared HKR127HCv(HZI) gene encoding another VH region
in order to improve the HKR127HCv(HZII) gene (see FIG
1) .
Particularly, the HKR127HCv(HZII) gene was
constructed by grafting the VH region of human DP7 gene
with the partial CDRl, 2, and 3 and one FR residue at
position 72 of mouse KR127 VH region. It was assumed
that the human CDRs and FR amino acid residues affected
the antigen-binding affinity of the antibody.
Therefore, HKR127HCv(HZI) gene was constructed by
PCR employing HKR127HCv(HZII) gene as a template.
17
CA 02351315 2001-05-17
On the other hand, a vector pRc/CMV-HC-HuS
(Accession Number: KCTC 0229BP) was used to synthesize
DNA sequence encoding human CH region as well as heavy
chain leader sequence, which is required in proper
secretion of the heavy chain.
Finally, HKR127HC(I) gene encoding a humanized
heavy chain was constructed by recombinant PCR for the
annealing of the heavy chain leader sequence,
HKR127HCv(HZI) gene, and the human CH gene (see FIG 2a).
The primers in these PCRs are synthetic
oligonucleotides described by SEQ ID NO: 1 to 12. PCR
was performed by using Taq DNA polymerase, and its
thermocycle was repeated 30 times, consisting of 1
minute at 94°C, 1 minute at 55°C, and then 1 minute at
72°C. Five pairs of oligonucleotides (SEQ ID NO: 1 and
2; 3 and 4; 5 and 6; 7 and 8; and 9 and 10) were used
as PCR primers, and the five PCR products (113 bp; 96
bp; 120 bp; 78 bp; and 87 bp, respectively) were
brought to annealing reaction. Then, the DNA fragments
containing the five PCR products were employed as
template of the recombinant PCR wherein primers
described by SEQ ID NO: 1 and 10 were used. Another
recombinant PCR was conducted to link the amplified
431-by DNA fragment to 1015-by DNA fragment which was
obtained by PCR using two primers (described by SEQ ID
NO: 11 and 12). The recombinant PCR employed two
primers described by SEQ ID NO: 1 and 12.
18
CA 02351315 2001-05-17
The final PCR product (HKR127HC(I), about 1431-bp)
encoding a recombinant heavy chain of humanized
antibody was introduced into the EcoRI-SalI site of
pBluescript SK(+) vector (Clontech), and the resulting
vector was designated pHKR127HC(I). The DNA sequence
of the inserted gene was determined by
dideoxynucleotide method.
To more humanize the HKR127HC(I), another
humanized heavy chain gene, HKR127(III), which has much
less number of mouse FR residues, was construc ted.
To construct the HKR127HC(III), HKR127H Cv(HZIII)
gene was constructed by PCR employing HKR127 HCv(HZII)
gene as a template. On the other hand, a vector
pRc/CMV-HC-HuS (Accession Number: KCTC 0229BP) was used
to synthesize DNA sequence encoding human CH region
as
well as heavy chain leader sequence, which is required
in proper secretion of the heavy chain.
Finally, HKR127HC(III) gene encoding a humanized
heavy chain was constructed by recombinant PCR for
annealing of the heavy chain leader sequence,
HKR127HCv(HZIII) gene, and the human CH gene (see FIG
2b) .
The primers in these PCRs are synthetic
oligonucleotides described by SEQ ID N0: 24 to 28. PCR
was performed by using Taq DNA polymerase, and its
thermocycle was repeated 30 times, consisting of 1
minute at 94°C, 1 minute at 55°C, and then 1 minute at
19
CA 02351315 2001-05-17
72°C. Three pairs of oligonucleotides (SEQ ID NO: 1
and 24; 25 and 26; and 27 and 28) were used as PCR
primers, and the three PCR products (179 bp; 141 bp;
and 87 bp, respectively) were brought to annealing
reaction. Then, the DNA fragments containing the three
PCR products were employed as template of the
recombinant PCR wherein primers described by SEQ ID NO:
1 and 28 were used. Another recombinant PCR was
conducted to link the amplified 431-by DNA fragment to
1015-by DNA fragment which was obtained by PCR using
two primers (described by SEQ ID NO: 11 and 12 ) . The
recombinant PCR employed two primers described by SEQ
ID N0: 1 and 12.
The final PCR product (HKR127HC(III), about 1431
bp) encoding a recombinant heavy chain of humanized
antibody was introduced into the EcoRI-SalI site of
pBluescript SK(+) vector (Clontech), and the resulting
vector was designated pHKR127HC(III). The DNA sequence
of the inserted gene was determined by
dideoxynucleotide method.
Example 2: Preparation of gene encoding humanized light
In order to prepare humanized light chain
containing variable region, we devised genes encoding
CA 02351315 2001-05-17
the light chain. First, we selected a human x
immunoglobulin gene that shows the highest homology of
amino acid sequence to the light chain of the mouse
monoclonal antibody KR127. As the result, a human x
immunoglobulin gene DPK12 was selected from GenBank
database. Then, we constructed HKR127KCv(HZII) gene
encoding a humanized VL region by grafting CDR1,
partial CDR2, and CDR3 and one FR residue at position
41 of the mouse KR127 VL region to the human DPK12 VL
region. The resulting humanized VL was not functional
in antigen-binding. To improve the HKR127KCv(HZII)
gene, we constructed HKR127KCv(HZI) gene encoding
another VL region (see FIG 3).
The HKR127KCv(HZI) gene was constructed by
grafting the VL region of human DPK12 antibody with a
few FR residues and CDRl, CDR2 and CDR3 of mouse KR127
VL (see FIG 3) .
On the other hand, a vector pKC-dhfr-HuS
(Accession Number: KCTC 0230BP) was used to synthesize
DNA sequence encoding human CL region as well as light
chain leader sequence, which is required in proper
secretion of the light chain.
Finally, HKR127KC(I) gene encoding a humanized
light chain was prepared by recombinant PCR for the
annealing of the PCR products, light chain leader
sequence, the HKR127KCv(HZI) gene, and the human CL
gene (see FIG 4).
21
CA 02351315 2001-05-17
The primers in these PCRs are synthetic
oligonucleotides described by SEQ ID N0: 13 to 18. The
thermocycle of these PCRs was repeated 30 times,
consisting of 1 minute at 94°C, 1 minute at 55°C, and 1
minute at 72°C . Two pairs of oligonucleotides ( SEQ I D
NO: 13 and 14; and SEQ ID N0: 15 and 16) were used as
PCR primers, and the two PCR products (101 by and 159
bp, respectively) were brought to annealing reaction.
Then, the DNA fragments containing the two PCR products
was employed as a template of recombinant PCR wherein
primers described by SEQ ID NO: 13 and 16 were used.
Another recombinant PCR was conducted to link the
amplified 248-by DNA fragment to 515-by DNA fragment
which was obtained by PCR using two primers (described
by SEQ ID NO: 17 and 18). The recombinant PCR employed
two primers described by SEQ ID NO: 13 and 18.
The final PCR product (HKR127KC(I), 736-bp)
encoding a recombinant light chain of humanized
antibody was introduced into the HindIII-SalI site of
pBluescript SK(+) vector (Clontech), and the resulting
vector was designated pHKR127KC(I). The DNA sequence
of the inserted gene was determined by
dideoxynucleotide method.
22
CA 02351315 2001-05-17
Example 3: Construction of expression vector containin
the humanized heavv chain aene
The pHKR127HC(I) or pHKR127HC(III) plasmid of
Example 1 was digested with SalI enzyme, and the both
ends of the vector was made blunt using Klenow enzyme
treatment. This DNA fragment was further digested with
NotI enzyme to obtain the gene encoding humanized heavy
chain.
On the other hand, pRc/CMV (Invitrogen) was cut
with XbaI enzyme, and the ends of the vector was made
blunt by treating with Klenow enzyme, and then digested
with NotI.
The humanized heavy chain gene and the linearized
vector were linked to give expression vector 'pCMV
HKR127HC or pCMV-HKR127(III)HC. The E. coli
transformant containing pCMV-HKR127HC or pCMV-
HKR127(III)HC was deposited in KCTC (Korean Collection
for Type Culture) (Accession Number: KCTC 0531BP and
KCTC 0691BP, respectively), and the expression vector
pCMV-HKR127HC and pCMV-HKR127(III)HC is shown in FIG 5a
and 5c, respectively.
23
CA 02351315 2004-07-20
Example 4: Construction of expression vector containin
the humanized light chain Gene
The pHKR127KC vector of Example 2 was digested
with HindIII and ApaI enzymes, and the resulting
fragment was inserted into HindIII-ApaT site of pCMV-
dhfr (Accession Number: KCTC 8671P) to give expression
vector pKC-dhfr-HKR127. The E. coli transformant
containing pKC-dhfr-HKR127 was deposited in KCTC
(Korean Collection for Type Culture) (Accession Number:
KCTC 0529BP), and the expression vector pKC-dhfr-HKR127
is shown in FIG 5b.
Example 5: Expression of humanized antibody in COS7
cells
COS7 cells were maintained in DMEM (Gibco)
supplemented by 10% calf serum at 37°C, under 5o C02
condition. The cells were inoculated in 100mm petri
dishes, and then incubated at 37°C overnight.
To express a humanized antibody HZKR127I, 5 ~g of
pCMV-HKR127HC or pKC-dhfr-HKR127 was diluted with 800
~.1 of OPTI MEM I (Gibco) , and 50 ~,1 of Lipofectamin ~
(Gibco) was also diluted with 800 ~.~.1 of OPTI MEM I.
These mixtures in 15-ml tubes were incubated at room
temperature for 15 minutes or more. In the meantime,
Tradermark
24 '
CA 02351315 2001-05-17
COS7 cells were washed twice with OPTI MEM I.
OPTI MEM I (6.4 ml) was added to the DNA-
Lipofectamin mixture, mixed well, and poured on the
COS7 cells. After the cells were cultured in a CO~
incubator for 72 hours, the medium was centrifuged, and
the supernatant was concentrated by ultrafiltration kit.
The concentration of antibody was determined by
Sandwich ELISA using anti-human IgG and anti-human IgG-
HRP (horseradish peroxidase) conjugate.
To express and obtain a humanized antibody
HZKR127III, the same protocol was repeated except using
pCMV-HKR127(III)HC instead of using pCMV-HKR127HC.
Example 6: Binding activity of humanized antibody to
HBV surface antigen pre-Sl
We prepared HBV surface antigen pre-Sl (amino acid
residue I-56; Kim and Hong, Biotechnology Letters,
17 : 871-876, 1995 ) and 1 ~tg of the purified pre-Sl was
coated on each well in microplates. After addition of
0, 0.25, 0.5, I, 2, 3, 4, 5, 7.5, 10, 20, or 40 ng of
the humanized antibodies prepared in Example 5,
indirect ELISA was performed, in which secondary
antibody was Fc-specific anti-human IgG-HRP conjugate.
The binding activities of the antibodies were
determined by measuring OD at 492 nm.
CA 02351315 2001-05-17
Purified mouse KR127 antibody was used as a
control, and ELISA of KR127 antibody was conducted
using Fc-specific anti-mouse IgG-HRP conjugate as a
secondary antibody. The result is presented in Table 1
and 2.
Table 1.
Binding activity of KR127 and HZKR127I to HBV
surface antigen pre-Sl (OD at 492 nm)
Amount
(ng) 0 0.250.5 1 2 3 4 5 7.5 10 20 40
Antibody
KR127 0.090.120.150.200.300.360.430.540.600.80 1.161.64
HZKR127I 0.090.120.170.260.350.430.600.710.791.12 1.481.77
Table 2.
Binding activity of HZKR127I and HZKR127III to HBV
surface antigen pre-Sl (OD at 492 nm)
Amount
(ng) 0 0.250.5 1 2 3 4 5 7.5 10 20 90
Antibody
HZKR127I 0.060.190.250.580.650.750.861.021.25 1.391.952.07
HZKR127III0.060.200.370.600.871.101.241.371.65 1.892.042.10
Example 7: Antigen-binding affinity of humanized
antibody to HBV surface antigen pre-Sl
Antigen-binding affinit~.~ to HBV surface antigen
26
CA 02351315 2001-05-17
pre-Sl was assayed by competitive ELISA method(Ryu et
al., J. Med. Virol., 52:226, 1997).
Binding reactions between the pre-Sl antigen (1 x
10-~ ~ 1 x 10-12 M) and the humanized antibody of
Example 5 (5 ng), or between the antigen (1 x 10-~ ~ 1
x 10-12 M) and control antibody KR127 (5 ng), were
performed at 37°C for 2 hours. Then the reaction
mixtures were added to 96-well microplates coated with
the 250 ng of antigen pre-Sl.
FIG 6a shows the affinity of two kinds of
antibodies. It was confirmed that the binding affinity
of the humanized antibody HZKR127I is almost same as
that of the mouse antibody KR127 (7 x 10' M-1).
FIG 6b shows the affinity of HZKR127III compared
with that of HZKR127I. The affinity of HZKR127III (5 x
10' M-1) was not much different from that (7 x 10' M-1)
of HZKR127I.
INDUSTRIAL APPLICABILITY
As shown above, the present invention provides
humanized antibody against HBV surface antigen pre-Sl,
which shows similar level of binding affinity when
compared with mouse monoclonal antibody, whereas
immunogenicity of the humanized antibody is remarkably
reduced. Thus, the humanized antibody of the present
27
CA 02351315 2001-05-17
invention may be useful for the prevention of HBV
infection and for the treatment of hepatitis B.
Those skilled in the art will appreciate that the
conceptions and specific embodiments disclosed in the
foregoing description may be readily utilized as a
basis for modifying or designing other embodiments for
carrying out the same purposes of the present invention.
Those skilled in the art will also appreciate that such
equivalent embodiments do not depart from the spirit
and scope of the invention as set forth in the appended
claims.
28
CA 02351315 2001-05-17
S~T~CE LISI~G
<llo> n~s-.~rwrs og sc~ Arro ~u~Y
~xr~ ~ cuss ooRPO~xxaN
<120> Hf~NrLED AN'1'~Ca3C SP~CI~'IC P'OR SURFACE ANT PRE-S1 OF REV AND
PREHARAT~1 TFD~F
<130> 10953-8/PAR
<150> ICt 1998-49663
<151> 1998-11-19
<160> 28
<170> ~OPATa11.5
<210>1
<211>26
<212>
<213>Artificial
Sequence
<220>
<223> synthetic oli~orn~cleotide primer 1
<400> 1
gagaattcac attcacgatg tacttg 26
<210>2
<21.1.>27
<212>DNpr
<213>Artificial
Sequence
<220>
<223> synthetic oligonucleotide primer 2
<400> 2
ggccccaggc ttcaccactt cagctcc 27
1
CA 02351315 2001-05-17
<210>3
<211>18
<212>L~r
<213>Artificial SequeaLCe
<220>
<223> synthetic oligonu~cleotida prizmr 3
<400> 3
gtgaagcctg gggcctca 18
<210>4
<211>27
<212>DI~1
<213>Artificial Sequemce
<220>
<223> synthetic o7.ig~oinucleotide prim~ar 4
<400> 4
agaactactg aatgegtagc cagaagc 27
<210>5
<211>27
<212>IB~i
<213>Artificial Sequ~ce
<220>
<223> synthetic olig~omucleotide primer 5
<400> 5
gcattcagta gttcttggat gaactgg 27
<210> 6
<211> 27
<212> I~r
2
CA 02351315 2001-05-17
<213> Artificial Sequ~cH
<220>
<223> synthetic oligoaucleotide primer 6
<400> 6
aatccgtcca atccactcaa gaccctg 27
<alo>7
<211>al
<212>Ll~
<213>Artificial
Sequence
<220>
<223> synthetic oligoxa~leotide primer 7
<400> 7
tggattggac ggatttatcc t 21
<210>8
<211>39
<212>IH~Pr
<213>Artificial
Sequence
<220>
<223> synthetic oligorn~cleotid~e primer 8
<400> 8
ggatttgtct gcagtcagtg tggccttgcc cbggaactt 39
<210>9
<211>39
<212>L~D1
<213>Artificial
Sequea~ce
<220>
<223> synthetic oligomucleotide primer 9
3
CA 02351315 2001-05-17
<400> 9
actgcagaca aatccacgag cacagcctac atggagctc 39
<210>10
<211>33
<a12>n~m
<213>Artificial
Sequence
<220>
<223> synthetic olic~omcleotid~e primer 10
<400> 10
gtcgtactct cttgcaca~ga aatagaccgc ogt 33
<210>11
<211>33
<212>Dar
<213>Artificial Sequeclce
<220>
<223> synthetic oligornicleotide primer 11
<400> 11
gcaagagagt acgacgaggc ttactggggc caa 33
<210>12
<211>26
<212>It~1
<213>Artificial
Sequence
<220>
<223> synthetic olig~oin~c7.eotide primer 12
<400> 12
cggtcgactc atttacccgg aga~ag 26
<alo> 13
4
CA 02351315 2001-05-17
<211> 2s
<212> It~1
<213> Artificial Sequence
<220>
<223> synthetic oligonucleotide priimr 13
<400> 13
caaagcttgg aagcaagatg gattca 26
<210>14
<211>36
<212>~1
<213>Artificial
Sequence
<220>
<223> synthetic oligonna7sotide primer 14
<400> 14
tttgg gtcatcaaga tatcccca~ ~c 36
<210>15
<217.>48
<212>It~1
<213>Artificial
Sequence
<220>
<223> synthetic oligonucleotide primer 15
<400> 15
atgacccaaa ctccactttc tttgtcg~gtt acccctggac aaccagcc 48
<210>16
<217.>39
<21a>n~
<213>Artificial sequence
<~20>
CA 02351315 2001-05-17
<223> synthetic oligornlccleotide pritmr 16
<400> 16
caccagatag attaggcgct ttggagactg goctggctt 39
<210>17
<211>39
<212>LIB
<213>Artificial
Sequa~ce
<220>
<223> synthetic olig~oa~cleotide primer 17
<400> 17
ctaatctatc tggt~gtctaa acbggactct acct 39
<210>18
<211>17
<212>It~a
<a13>Artificial
sequence
<aao>
<223> synthetic olig~orn~cleotiae primer 18
<400> 18
gaagtcgacc taacact 17
<210>19
<211>115
<212>PRT
<213>Artificial
Sequence
<220>
<223> Variable region of heavy chain in manse Idt127 antibody
<400> 19
Gln Val Gln Len Gln Gln Ser Gly Pro Glu Iai Val Lys Pro Gly Ala
1 5 10 15
6
CA 02351315 2001-05-17
ser val Lys ne ser cys r~~s Ala ser GLy Tyr Ala Phe ser ser ser
20 25 30
Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln GLy Len G7u Txp I7e
35 40 45
Gly Ax~g Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asa Gly Lys Phe
50 55 60
Lys Gly Lys Ala Thr Len Thr Ala Asp Lys Sex 9~ Sex Thr Ala Tyr
65 70 75 80
Met Gln Len Ser Ser Len Thr Sex Val Asp Ser Ala Val Tyr Pha Cys
85 90 95
Ala Arg Glu Tyr Asp Glu Ala Tyr Txp Gly G1n G1y Thr Len V~l Thr
100 105 110
val Ser Ala
<210>20
<211>115
<212>PRT
<213>Artificial
Sequence
<220>
<223> variable region of hs~anized heavy chain H~t127HC(HZI)
<400> 20
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pm Gly Ala
1 5 10 15
Ser Val Lys Val Ser G~~s hys Ala Ser GLy Tyr Ala Phe Ser Ser Ser
20 25 30
Trp Met lsar Trp Val Azg Glu Ala Pro Gly Gln Gly Len Glu Txp I7e
35 40 45
7
CA 02351315 2001-05-17
Gly Arg Ile Tyr Pro Gly Asp Gly Asp ait Asn Tyr Ala Gln Lys Pha
50 55 60
Gln Gly Lys Ala Thr Leru 7Sit Ala Asp Lys 9er ~hr Ses Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Sex C~Lu Asp lhr Ala Val Tyr Pha Cys
85 90 95
Ala Arg Glu Tyr Asp Glu Ala Tyr gp Gly G1n Gly Thr Leu V~l Tts
100 105 110
Val Ser Ser
115
<210>21
<all>115
<212>PRT
<213>Artificial
Sequ~ce
<220>
<223> Variable regiaa~ of h~niaed heavy chain ~t7,27I~C(HZ~)
<400> 21
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Las Pm Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cars Iys Ala Ser Gly Tyr Zhr Pha Thr Ser Sa
20 25 30
Trp Met Asn Txp Val Arg Gln Ala Pro Gly Gln C~Ly Leu Ghi Txp Mat
35 40 45
Gly Arg Ile Tyr Pro Gly Asp Gly Asp ~r Asn Tyr Ala Gln Lys Pha
50 55 60
G3n Gly Arg Val Thr Met ~r Ala Asp Iys 9er ~s Set Thr Vbl Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg 9er Glu Asp ~r Ala Val Tyr Tyr Cys
8
CA 02351315 2001-05-17
85 90 95
Ala Arg Glu Tyr Asp Glu Ala Tyr Trp Gly G1n Gly Tts Leu V~l Thr
100 105 110
Val Ser Ser
115
<210>22
<211>113
<212>PRT
<213>Artificial
Sequence
<220>
<223> variable region of light chain in mouse IGt127 antibody
<400> 22
Asp Ile Len Met Thr Gln lhr Pro Len Its Len 9er Val Tls I7e Gly
1 5 10 15
Gln Pro Ala Ser Ile Set C~8 Iys 9er 9er G1n gar Len Len Tyr Ser
20 25 30
Asn Gly Lys Thr Tyr Leiu Asn Tip Ieu Ieu G1n Azg Pm Gly Gln Sar
35 40 45
Pro Lys Arg Len Ile Tyr Len Val Ser I~rs Leu~ Asp Sew Gly Val Pm
50 55 60
Asp Arg Phe Thr Gly Ser Gly 9er Gly ~ Asp Phe Tls Len Lys I7e
65 70 75 80
Ile Arg Val Glu Ala Glu Asp Len GLy Val Tyr Tyr Cys V~l Gln G~
85 90 95
Thr His Phe Pro Gln Thr Phe Gly GLy Gly Zhr Iys Len G~ I7e Lys
100 105 110
9
CA 02351315 2001-05-17
<210>23
<211>113
<212>PRT
<213>Artificial
Sequence
<220>
<223> variable regiaai of h~nized light chain
<400> 23
Asp Ile Lau biet Thr Gln Thr Pm Leu 9er Leu 9er Val TES Pm Gly
1 5 10 15
Gln Pro Ala Ser Ile Ses Cys lays 9er Sar C;ln 9er Leu Leu Tyr Ser
20 25 30
Asn Gly Lys Thr Tyr Leu Asn Trp Ieu Lsu Gln Iys Pm Gly Gln Sec
35 40 45
Pro Lys Arg Leu Ile Tyr Leu Val Ses hys Leu Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly 9er Gly T~ Asp Phe Tls Lai Lys I7e
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Val Gln Gly
85 90 95
Thr His Phe Pro Gln Thr Phe Gly GLy Gly Thr Iys Val Glu Ile Lys
100 105 110
<210>24
<211>27
<212>T~
<213>Artificial
Sequence
<220>
<223> synthetic oligoaucleotide primer 24
CA 02351315 2001-05-17
<400> 24
~~3~t99t9a ~J9~ 27
<210>25
<211>27
<212>Il~r
<213>Artificial
Sequence
<220>
<223> synthetic oligonucleotide primer 25
<400> 25
agttcttgga tgaactgggt gcgacga 27
<210>26
<211>27
<21Z>L~1
<213>Artificial
Sequence
<220>
<223> synthetic oligornicleotide primer 26
<400> 26
gctcgtggat ttgtctgcag tcattgt 27
<210>27
<211>27
<212>~r
<213>Artificial Sequence
<220>
<223> synthetic oligomucleotide primer 27
<400> 27
gacaaatcca cgagcacagt ctacatg 27
11
CA 02351315 2001-05-17
<210>28
<211>27
<212>Iii
<213>Artificial
Sequemce
<220>
<223> synthetic oligom~cleotide primer 28
<400> 28
gtcgtactct ctcgcacagt aatacac 27
12
